Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate

December 19, 2023

https://www.globenewswire.com/news-release/2023/12/18/2798137/0/en/Kronos-Bio-Announces-Pipeline-Update-and-p300-KAT-Inhibitor-Development-Candidate.html

Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2

Read more at globenewswire.com

Related news for (KRON)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.